| Lydia M Radke, LCSW | |
|
315 E Main St Ste 202, Hillsboro, OR 97123-4173 | |
| (971) 238-4453 | |
| Not Available |
| Full Name | Lydia M Radke |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 315 E Main St Ste 202, Hillsboro, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174816342 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | L4457 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lydia M Radke, LCSW 315 E Main St Ste 202, Hillsboro, OR 97123-4173 Ph: (971) 238-4453 | Lydia M Radke, LCSW 315 E Main St Ste 202, Hillsboro, OR 97123-4173 Ph: (971) 238-4453 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.
United States Department of Health and Human Services has announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), will administer the contracts.
Optimer Pharmaceuticals, Inc. today announced that it has submitted the first section of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI. Optimer anticipates completing the submission in the fourth quarter of 2010 and plans to request priority review, which, if granted, could lead to an FDA decision on the NDA in the second quarter of 2011.
› Verified 5 days ago
Meghan Thivierge, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 971 Sw Walnut St, Hillsboro, OR 97123 Phone: 503-640-5297 Fax: 503-640-5780 | |
Kara Rae Kazemba, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 328 W Main St Ste C, Hillsboro, OR 97123 Phone: 971-238-4408 | |
Lindsay Elise Balboa, CSWA Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4950 Ne Belknap Ct, Suite 205, Hillsboro, OR 97124 Phone: 503-560-5822 Fax: 888-503-2864 | |
Brenda Jo Wilkes, BRENDA WILKES, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 21210 Nw Mauzey Rd., Hillsboro, OR 97124 Phone: 503-439-9531 Fax: 503-531-3841 | |
Mrs. Jennifer Bergmans Ybarra, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 9620 Ne Tanasbourne Dr Ste 300-75, Hillsboro, OR 97124 Phone: 503-481-3512 | |
Dean Bichsel, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5240 Ne Elam Young Pkwy Ste 100, Hillsboro, OR 97124 Phone: 503-846-4555 | |
Maija Ryan, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3000 Nw Stucki Pl, #150, Hillsboro, OR 97124 Phone: 503-953-5535 Fax: 503-295-4036 |